menu
    • menu
    [{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"LIPAC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Huons CO., LTD \/ Huons","highestDevelopmentStatusID":"8","companyTruncated":"Huons CO., LTD \/ Huons"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Huons CO., LTD \/ Lupin Ltd","highestDevelopmentStatusID":"14","companyTruncated":"Huons CO., LTD \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Huons CO., LTD

    Menu

    Huons CO., LTD

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Huons CO., LTD

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Huons CO., LTD

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lupin, Huons Sign Deal To Commercialize Cyclosporine in Mexico

                            Details : The agreement aims for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, generic of Restasis, in Mexico.

                            Brand Name : Restasis-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Huons CO., LTD

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Huons CO., LTD

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : LIPAC Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons

                            Details : Clinical Study Report for a Phase 2A marker lesion clinical trial in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer treated with LiPax has been finalized. First milestone payment to LIPAC under the collaboration signed in In ...

                            Brand Name : LiPax

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 10, 2020

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : LIPAC Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth